NCT02172430已完成3 期
A Multiple Dose Comparison of Tiotropium 18 μg Inhalation Capsules and Oxitropium MDI (2 Puffs of 100 μg) in a One-year, Open-Label, Safety and Efficacy Study in Patients With COPD
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 161
- 主要终点
- Occurrence of Adverse Events
研究概览
简要总结
The objective of this study is to investigate the long-term safety of Ba 79 BR (tiotropium) powder inhalation in patients with COPD using oxitropium bromide (Tersigan) as a comparator. Secondarily, the long-term efficacy of Ba 679 BR is also investigated
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patients with COPD (chronic bronchitis, emphysema) whose symptoms are stable and who satisfy the following criteria
- •Patients with FEV1.0 of <=70% of predicted normal and FEV1.0/FVC of <=70% in the screening test (The FEV1.0 value should also be <=70% of predicted normal on the starting day of administration (visit 2).)
- •Patients with a smoking history (<number of cigarettes smoked a day x number of smoking years> is >=200.)
- •Male or female patients aged >=40 years old
排除标准
- •Patients complicated with bronchial asthma, making the assessment of drug efficacy against COPD difficult
- •Patients using oral corticosteroid medication at a dose in excess of the equivalent 10 mg/day of prednisolon
- •Patients with glaucoma
- •Patients with symptomatic prostatic hypertrophy
- •Patients with hypersensitivity to anticholinergic drugs or powder inhalants
- •Patients with serious complication who are judged by the investigator to be inappropriate as the subjects of study
- •Patients demonstrating clinically problematic abnormal laboratory test values (general blood test, biochemical test, urinalysis). Those showing Glutamic Oxaloacetic Transaminase (GOT) and Glutamic PyruvicTransaminase (GPT) twice the upper limit of the normal range, bilirubin 1.25 times or creatinine 1.25 times of the upper limit of normal range are excluded.
- •Patients with a recent history of myocardial infarction or heart failure (i.e. within 3 months before the screening test)
- •Patients with arrhythmia requiring the treatment with drugs
- •Patients for whom the concomitant use of beta-blocker cannot be prohibited.
- •Patients who began treatment with an ACE inhibitor within 1 month before the screening test
- •Patients with tuberculosis (currently active) or with definite sequela of tuberculosis
- •Patients with a recent history of carcinoma (excluding basal cell carcinoma) (i.e. within the past 5 years)
- •Patients with a history of cystic fibrosis and bronchiectasis
- •Patients with recent onset of upper airway infection (i.e. within 1 month before the screening test)
- •Patients who have taken an investigational drug within one month or within period six times of half-lives of that drug (whichever is longer) before the screening test.
- •Women who are pregnant or who may become pregnant, or those breast feeding
- •Other than above, those who are judged by the investigator to be inappropriate as the subjects of study
研究组 & 干预措施
Tiotropium
Experimental
干预措施: Tiotropium powder inhalation capsules (Drug)
Oxitropium bromide
Active Comparator
干预措施: Tersigan® (Drug)
结局指标
主要结局
Occurrence of Adverse Events
时间窗: up to 52 weeks
Changes from baseline in Blood Pressure / Heart Rate
时间窗: up to 52 weeks
Changes from baseline in ECG
时间窗: up to 52 weeks
Changes from baseline in laboratory tests
时间窗: up to 52 weeks
次要结局
- Changes from baseline in Trough Forced vital capacity (FVC) response(week 24 and 52)
- Changes from baseline COPD clinical symptoms (Cough frequency, sputum amount, severity of short breath, nocturnal sleep)(up to 52 weeks)
- Changes from baseline in Trough Forced expiratory volume in one second (FEV1.0) response(week 24 and 52)
- Changes from baseline in FVC at 1 hr post-dosing(week 24 and 52)
- Patient's impression(week 24 and 52)
- Physician's global evaluation(week 24 and 52)
- Changes from baseline in FEV1.0 at 1 hr post-dosing(week 24 and 52)
- Frequency of rescue use of β2 stimulants(up to 2 weeks)
- Changes from baseline in Quality of Life QOL (St George's Respiratory Questionnaire (SGRQ) and Airways Questionnaire-20 (AQ20), if possible)(week 24 and 52)
研究者
相似试验
已完成
3 期
Efficacy and Safety of Tiotropium Compared to Salmeterol and Placebo in Patients With Chronic Obstructive Bronchitis (COPD)Pulmonary Disease, Chronic ObstructiveNCT02173691Boehringer Ingelheim584
已完成
3 期
Multiple Dose Comparison of Tiotropium Inhalation Capsules, Salmeterol Inhalation Aerosol and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic ObstructiveNCT02172287Boehringer Ingelheim623
已完成
1 期
Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic ObstructiveNCT02231177Boehringer Ingelheim47
已完成
3 期
A Comparison of 18g of Tiotropium Inhalation Capsules Once Daily and Atrovent Metered Dose Inhaler (2 Puffs of 20g, 4 Times Daily) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic ObstructiveNCT00239434Boehringer Ingelheim200
招募中
3 期
The effectiveness of Tiotropium bromide in patients with severe asthmaIRCT20181015041353N1Zahedan University of Medical Sciences60